Related Experiment Video

Updated: May 29, 2026

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications
09:50

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications

Published on: August 20, 2021

Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β

Amanda J Edgley1, Henry Krum, Darren J Kelly

  • 1Department of Medicine, St. Vincent's Hospital, University of Melbourne, Victoria, Australia.

Cardiovascular Therapeutics
|September 3, 2011
PubMed

Insights

Targeting transforming growth factor-beta (TGF-β) offers a promising strategy to combat pathological fibrosis in the heart. Inhibiting TGF-β may prevent extracellular matrix accumulation and improve heart function in chronic heart failure.

Area of Science:

  • Cardiology
  • Biomedical Science
  • Pathology

Background:

  • Chronic heart failure (CHF) is a significant health concern, exacerbated by pathological extracellular matrix accumulation.
  • This fibrosis leads to ventricular stiffening and reduced contractility, impacting heart function.
  • Inflammatory processes and key cytokines like transforming growth factor-beta (TGF-β) drive cardiac fibrosis.

Purpose of the Study:

  • To review the therapeutic potential of targeting TGF-β for preventing pathological fibrosis in the heart.
  • To highlight the unmet clinical need for therapies addressing profibrotic inflammatory pathways in CHF.
  • To explore strategies inhibiting cytokine activation and extracellular matrix deposition.

Main Methods:

  • Literature review focusing on TGF-β's role in cardiac fibrosis.
  • Analysis of current therapeutic strategies and their limitations.
  • Exploration of novel therapeutic targets within inflammatory and fibrotic pathways.

Main Results:

  • Transforming growth factor-beta (TGF-β) is a critical mediator of cardiac fibrosis.
  • Current treatments do not directly address the underlying profibrotic inflammation in CHF.
  • Inhibiting TGF-β presents a potential therapeutic avenue for preventing heart failure progression.

Conclusions:

  • Targeting TGF-β is a viable strategy to prevent pathological cardiac fibrosis.
  • Interventions aimed at inhibiting proinflammatory cytokines and ECM accumulation are crucial for CHF prevention.
  • Further research into TGF-β inhibitors could lead to novel treatments for heart failure.

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.